336 related articles for article (PubMed ID: 23842430)
1. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
3. Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.
He Y; Wang Y; Struble EB; Zhang P; Chowdhury S; Reed JL; Kennedy M; Scott DE; Fisher RW
Virol J; 2012 Sep; 9():217. PubMed ID: 23006741
[TBL] [Abstract][Full Text] [Related]
4. An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies.
Xu C; Meng X; Yan B; Crotty S; Deng J; Xiang Y
Virology; 2011 Sep; 418(1):67-73. PubMed ID: 21810533
[TBL] [Abstract][Full Text] [Related]
5. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
[TBL] [Abstract][Full Text] [Related]
6. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
7. Adaptive Immune Response to Vaccinia Virus LIVP Infection of BALB/c Mice and Protection against Lethal Reinfection with Cowpox Virus.
Shchelkunov SN; Sergeev AA; Yakubitskiy SN; Titova KA; Pyankov SA; Kolosova IV; Starostina EV; Borgoyakova MB; Zadorozhny AM; Kisakov DN; Shulgina IS; Karpenko LI
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452494
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
[TBL] [Abstract][Full Text] [Related]
9. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model.
Chen Z; Earl P; Americo J; Damon I; Smith SK; Yu F; Sebrell A; Emerson S; Cohen G; Eisenberg RJ; Gorshkova I; Schuck P; Satterfield W; Moss B; Purcell R
J Virol; 2007 Sep; 81(17):8989-95. PubMed ID: 17581986
[TBL] [Abstract][Full Text] [Related]
10. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
[TBL] [Abstract][Full Text] [Related]
11. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
12. Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.
Matho MH; Schlossman A; Meng X; Benhnia MR; Kaever T; Buller M; Doronin K; Parker S; Peters B; Crotty S; Xiang Y; Zajonc DM
PLoS Pathog; 2015 Sep; 11(9):e1005148. PubMed ID: 26325270
[TBL] [Abstract][Full Text] [Related]
13. The generation of CD8+ T-cell population specific for vaccinia virus epitope involved in the antiviral protection against ectromelia virus challenge.
Gierynska M; Szulc-Dabrowska L; Dzieciatkowski T; Golke A; Schollenberger A
Pathog Dis; 2015 Dec; 73(9):ftv088. PubMed ID: 26474845
[TBL] [Abstract][Full Text] [Related]
14. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
16. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
17. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
Braxton CL; Puckett SH; Mizel SB; Lyles DS
J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
[TBL] [Abstract][Full Text] [Related]
18. Phage display antibodies against ectromelia virus that neutralize variola virus: Selection and implementation for p35 neutralizing epitope mapping.
Khlusevich Y; Matveev A; Baykov I; Bulychev L; Bormotov N; Ilyichev I; Shevelev G; Morozova V; Pyshnyi D; Tikunova N
Antiviral Res; 2018 Apr; 152():18-25. PubMed ID: 29427674
[TBL] [Abstract][Full Text] [Related]
19. Heterotypic immunity against vaccinia virus in an HLA-B*07:02 transgenic mousepox infection model.
Kumar A; Suryadevara NC; Wolf KJ; Wilson JT; Di Paolo RJ; Brien JD; Joyce S
Sci Rep; 2020 Aug; 10(1):13167. PubMed ID: 32759969
[TBL] [Abstract][Full Text] [Related]
20. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
